Your browser doesn't support javascript.
loading
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4.
Weiner, Michael W; Veitch, Dallas P; Miller, Melanie J; Aisen, Paul S; Albala, Bruce; Beckett, Laurel A; Green, Robert C; Harvey, Danielle; Jack, Clifford R; Jagust, William; Landau, Susan M; Morris, John C; Nosheny, Rachel; Okonkwo, Ozioma C; Perrin, Richard J; Petersen, Ronald C; Rivera-Mindt, Monica; Saykin, Andrew J; Shaw, Leslie M; Toga, Arthur W; Tosun, Duygu; Trojanowski, John Q.
Afiliação
  • Weiner MW; Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.
  • Veitch DP; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
  • Miller MJ; Department of Medicine, University of California, San Francisco, California, USA.
  • Aisen PS; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
  • Albala B; Department of Neurology, University of California, San Francisco, California, USA.
  • Beckett LA; Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.
  • Green RC; Northern California Institute for Research and Education (NCIRE), Department of Veterans Affairs Medical Center, San Francisco, California, USA.
  • Harvey D; Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.
  • Jack CR; Northern California Institute for Research and Education (NCIRE), Department of Veterans Affairs Medical Center, San Francisco, California, USA.
  • Jagust W; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
  • Landau SM; Department of Neurology, University of California Irvine School of Medicine, Irvine, California, USA.
  • Morris JC; Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California, USA.
  • Nosheny R; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Broad Institute Ariadne Labs and Harvard Medical School, Boston, Massachusetts, USA.
  • Okonkwo OC; Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California, USA.
  • Perrin RJ; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Petersen RC; Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA.
  • Rivera-Mindt M; Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA.
  • Saykin AJ; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Shaw LM; Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Toga AW; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Tosun D; Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.
  • Trojanowski JQ; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
Alzheimers Dement ; 19(1): 307-317, 2023 01.
Article em En | MEDLINE | ID: mdl-36209495
INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022. METHODS: ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials. RESULTS AND DISCUSSION: ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos